Stock News

Enter Stock SymbolWill Cerner Corporation's (NASDAQ:CERN) Earnings Grow In The Year Ahead?Based on Cerner Corporation's (NASDAQ:CERN) earnings update in June 2019, it seems that analyst forecasts are fairly...Wed, 11 Sep 2019 17:55:57 +0000 —Read more…Cybersecurity a Top Priority for Healthcare: 3 Stocks to WatchAs cybersecurity is the need of the hour for U.S. healthcare companies, let's keep an eye on three stocks.Wed, 11 Sep 2019 13:10:01 +0000 —Read more…Cerner Declares Quarterly DividendCerner (CERN) announced its Board of Directors has declared a cash dividend to stockholders of $0.18 per issued and outstanding share. The cash dividend will be payable on Oct. 9, 2019, to shareholders of record as of the close of business on Sept. 25, 2019. Cerner intends to pay regular quarterly cash dividends, with future declarations subject to approval by its Board of Directors and their determination that the declaration of dividends remains in the best interests of Cerner and its shareholders. The decision of whether to pay future dividends and the amount of any such dividends will be based on the Company’s financial position, results of operations, cash flows, capital requirements, the requirements of applicable law and any other factors the Board of Directors may deem relevant.Wed, 11 Sep 2019 13:01:00 +0000 —Read more…C-level exec will leave after preparing Cerner for next 'wave of disruptive innovation'While Jeff Townsend, who ranked as the Kansas City area's fourth-highest-paid public company executive, is retiring from Cerner at the end of the year, he will stay on in an advisory role as he expects "another wave of disruptive innovation is just around the corner."Tue, 10 Sep 2019 18:27:52 +0000 —Read more…How Cerner Is Capitalizing on Growth in Healthcare ITInvestors can expect Cerner to grow its top line by 6% to 9% over the next five years.Tue, 10 Sep 2019 09:59:00 +0000 —Read more…Cerner Executive Jeff Townsend Announces Retirement“For more than 30 years, Jeff has worked diligently to position Cerner for key opportunities and prepared us to drive the next wave of health care innovation,” said Brent Shafer, chairman and CEO, Cerner. “On behalf of the board of directors as well as Cerner’s associates worldwide, I want to thank Jeff for his extraordinary contributions to Cerner. Since 1985, Jeff has led initiatives that helped shape Cerner’s identity, including the discovery and acceleration of first-of-a-kind solutions.Mon, 09 Sep 2019 20:05:00 +0000 —Read more…Cerner Corp (CERN) Exec. VP & CFO Marc G Naughton Sold $1.6 million of SharesExec. VP & CFO of Cerner Corp (30-Year Financial, Insider Trades) Marc G Naughton (insider trades) sold 24,110 shares of CERN on 09/06/2019 at an average price of $67.58 a share. Continue reading...Fri, 06 Sep 2019 23:15:05 +0000 —Read more…Cerner Layoffs 2019: 16 Things to Know About the CERN Job CutsCerner layoffs are on the way as the company looks to reduce its workforce.Source: Eyesonmilan / Shutterstock.com Here's what to know about the layoffs coming for Cerner (NASDAQ:CERN) employees. * The company is laying off a total of 255 employees in the U.S. * This has the company alerting employees about the layoffs today. * Employees affected by the layoffs will be receiving severance pay. * They also won't be leaving immediately. * Instead, their last day of work will be Nov. 5, 2019. * The company also notes that it will continue to hire more employees. * It says that these opportunities will be available to current employees. * Cerner also points out that these layoffs are affecting employees of all levels. * This includes some executives that will be part of the layoffs. * Roughly half of the 255 employees being laid off will be from its offices in Kansas City. * Cerner also mentions that it is laying off employees in the U.K. as well. * However, the company doesn't go into detail about these lay offs. * Instead, it simply says that only a small number of employees are affected. * The company currently employs about 14,000 people in the U.S. and 30,000 people around the world. * The Cerner layoffs are part of the company's effort to increase its operating margin. * It wants to reach an operating margin of 20% in the fourth quarter of 2019 and 22.5% for the fourth quarter of 2020. * 7 Deeply Discounted Energy Stocks to Buy You can follow these links to learn more about the Cerner layoffs.InvestorPlace - Stock Market News, Stock Advice & Trading TipsCERN stock was down slightly as of Wednesday afternoon. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Deeply Discounted Energy Stocks to Buy * 7 Stocks to Buy In a Flat Market * 10 Stocks to Buy to Ride China's Emerging Wealth As of this writing, William White did not hold a position in any of the aforementioned securities.The post Cerner Layoffs 2019: 16 Things to Know About the CERN Job Cuts appeared first on InvestorPlace.Wed, 04 Sep 2019 18:01:53 +0000 —Read more…Cerner begins layoffs that will affect hundreds of employeesCerner is laying off 255 people at its U.S. operations as part of a larger effort to cut costs and boost operating margins. About half of the layoffs, which are being announced today, will occur at the company's Kansas City-area offices.Wed, 04 Sep 2019 15:03:16 +0000 —Read more…5 Stocks These Socially Responsible Gurus Agree OnCommon holdings of Al Gore and Jerome Dodson as of the 2nd quarter Continue reading...Tue, 27 Aug 2019 19:13:24 +0000 —Read more…SYNH or CERN: Which Is the Better Value Stock Right Now?SYNH vs. CERN: Which Stock Is the Better Value Option?Tue, 27 Aug 2019 13:40:01 +0000 —Read more…Does Cerner Corporation (NASDAQ:CERN) Have A Good P/E Ratio?Today, we'll introduce the concept of the P/E ratio for those who are learning about investing. We'll apply a basic...Mon, 26 Aug 2019 13:32:13 +0000 —Read more…Cerner Corp (CERN) EVP and Chief Client Officer John Peterzalek Sold $2 million of SharesEVP and Chief Client Officer of Cerner Corp (30-Year Financial, Insider Trades) John Peterzalek (insider trades) sold 27,484 shares of CERN on 08/22/2019 at an average price of $72.11 a share. Continue reading...Fri, 23 Aug 2019 22:15:06 +0000 —Read more…Cerner (CERN) Down 1.7% Since Last Earnings Report: Can It Rebound?Cerner (CERN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.Fri, 23 Aug 2019 13:31:01 +0000 —Read more…Argus Stock Research: Upgrading Cerner Corp. (CERN) to BuyThis excerpt was brought to you using the Research Reports feature available through Yahoo Finance Premium. The Argus analyst rating on Cerner Corp. (CERN) has been raised to BUY, from HOLD. Cerner is involved in several fast-growing segments of information software products, professional services, and medical device integration for healthcare providers.Thu, 22 Aug 2019 19:00:51 +0000 —Read more…Starboard Value shrinks stake in CernerNow that Starboard Value has two seats on Cerner's board and a say in operational and cost structures, the activist investor is decreasing its already small stake in the health IT company.Fri, 16 Aug 2019 14:47:29 +0000 —Read more…Cerner jumps into senior living with latest ventureCerner has partnered with a planned wellness community development company to provide health care services to seniors using the company's technology.Mon, 12 Aug 2019 19:59:01 +0000 —Read more…Does Cerner Corporation (NASDAQ:CERN) Create Value For Shareholders?Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...Fri, 09 Aug 2019 13:23:19 +0000 —Read more…Cerner exec: New partnership will use data to drive down drug costsThe pilot program and partnership between Cerner and Duke Clinical Research Institute has the potential to make clinical research more cost effective through automating and analyzing data collection.Thu, 08 Aug 2019 19:59:36 +0000 —Read more…3 Keys to Investing in Next-Gen Healthcare StocksPicture a bizarre clothing store for a moment …Source: Shutterstock You walk in. An employee sizes you up and asks you if there's anything in particular you're looking for. After learning that you're a size "large" and that you'd like some new dress shirts, the employee takes you to a table covered with them. All of the shirts are the same size. All XL, extra-large."Strange," you think, and go to another table covered with shirts. All the shirts are the same size. All XL.InvestorPlace - Stock Market News, Stock Advice & Trading Tips"Stranger," you think, and go to another table covered with shirts. Once again, all the shirts are the same size. All XL.Sensing your confusion, the employee explains the store's "one size fits all" policy. The owners know people come in many shapes and sizes, but XL is the only size of clothes they can get from their suppliers.You walk out of the "one size fits all" store, thinking it's one of the most ridiculous things you've ever seen.A "one size fits all" clothing store isn't much different than America's healthcare system.Lacking the resources to treat us as individuals -- with different genetic makeups, different diets, and living in different environments -- doctors frequently resort to treating patients with "one size fits all" procedures and medicines. And since most doctors rush patients in and out of the office to boost profits, the pressure to use sub-par, "one size fits all" treatments is massive.Don't get me wrong: Our approach to health and medicine is light years ahead of where it was in the 1800s. Bloodletting is no longer a "go to" move for doctors.However, many of the decisions made by today's healthcare professionals will look medieval when compared to the treatments of the near future. They simply don't take into account that every case is different -- that we are all unique. Take the drug commercials you see on television … which go on to list lots of horrible side effects of popular drugs (which don't work for everyone who takes them).Soon, we'll say goodbye to those types of treatments. That's because the age of customized, "precision" healthcare is getting started. The result will be a massively improved healthcare system … and some of the biggest wealth building opportunities of your life.In today's essay, I'll describe the three key innovations that will take us into the age of precision medicine. Investors will want to pay attention. In America, we spend $3.5 trillion -- about 18% of GDP -- on healthcare. When something big happens in healthcare, it creates giant ripple effects in the economy that enrich those who know what's happening. Trillion-Dollar Innovation 1: Genome SequencingEvery cell in your body has a set of genetic instructions that dictate what you look like, what your athletic abilities are, what your mental abilities are, what diseases you're likely to get, and dozens of other key things that make you YOU.This set of instructions is called your genome. Determining exactly what your genome says is a process called genome sequencing.In 2003, an international research organization called The Human Genome Project sequenced a human genome for the first time. The project's price tag was an enormous $3 billion.Thanks to incredible advances in computing power, that same sequencing can be performed today for less than $1,000. And in a few years the price will be as low as a dinner for two.Genome sequencing is a critical part of precision medicine because it allows medical professionals to get an incredibly detailed analysis of who you are. As a result of this information, doctors can recommend treatments that are right for you.Sixteen years ago, getting this kind of detailed information was prohibitively expensive. But now that costs are down more than 99% and poised to go down even more, genome sequencing is about to go mainstream.Genetic testing will become part of regular medical care … just like taking your pulse and your blood pressure. It's going to usher in an era of much more effective healthcare. In large part to innovation 2 … Trillion-Dollar Innovation 2: Digital Patient RecordsIt's one thing to have lots of information. It's an entirely different -- and more valuable -- thing to be able to analyze that information and use it to make quality decisions.This is where digital patient records come in.Genome sequencing will produce vast amounts of information that will need to be stored and analyzed. Just as the processing power of our computers has increased by leaps and bounds since 2003, our ability to collect and store information has increased as well. This continued growth is a key part of precision medicine. That's because genome sequencing is going to generate a stupendous amount of information.It is predicted that the amount of storage capacity for all human genome data will increase to 40 exabytes by 2025. To put that into perspective, experts believe all videos on YouTube will require 1-2 exabytes of storage and Twitter will require .001 to .017 exabytes.As for analyzing all that data, we come to Innovation 3 … Trillion-Dollar Innovation 3: AI DoctorsAs you can guess, we're not going to sift through some of the world's largest data sets with a pen and paper in hand.We're going to use artificial intelligence (AI) to perform advanced data analysis. AI programs will sift through data to identify treatments that work for patients with specific genetic conditions.These programs will be able to do more "thinking" in one minute than millions of doctors could do in a decade. It's going to revolutionize healthcare.In fact, I believe that within the next 30 years, AI will know how various combinations of molecules will affect patients on the individual level. We'll have giant databases of patients and their genetic makeups … and we'll be able to test new drugs with computer simulations. The time it takes to devise, test, and produce new life-saving drugs will be massively condensed. Plus, the cost of doing it all will plummet.We'll have vast databases of human genomes and the ability to create and test new customized treatments in seconds. It could easily become the most valuable technology on the planet. Again, this is many years away, but I believe it's going to happen. Summing UpOne size fits allThanks to the technological limitations of the past, our healthcare system is based on treatments that are not tailored to your genetic makeup. We're using "shotgun" approaches instead of targeted approaches.However, thanks to cheap and widespread genome sequencing, digital record keeping, and artificial intelligence, we're about to enter an amazing era of precision, personalized medicine.Over the next 20 years, the healthcare system we know and don't love will change dramatically. We'll look back at some of today's treatments as medieval.Remember: In America, we spend $3.5 trillion -- about 18% of GDP -- on healthcare. When something big happens in the industry, it creates giant ripple effects. That's why the precision medicine revolution is one of the greatest wealth building opportunities of your life.The opportunities are not in the old school big pharma names like Johnson & Johnson. They are in precision medicine and the technologies that will enable it.Everything from digital records company Cerner (NASDAQ:Cern) to gene testing pioneer Illumina (NASDAQ:ILMN) to contract research services firm IQVIA Holdings (NYSE:IQV) will take the lead in the future of precision medicine.And keep an eye on the IPO market here as well. We'll see waves of early stage companies going public … many with the potential to not only revolutionize medicine, but revolutionize your net worth as well.Matthew McCall is the founder and president of Penn Financial Group, an investment advisory firm, as well as the editor of Investment Opportunities and Early Stage Investor. He has dedicated his career to getting investors into the world's biggest, most revolutionary trends BEFORE anyone else. The power of being "first" gave Matt's readers the chance to bank +2,438% in Stamps.com (STMP), +1,523% in Ulta Beauty (ULTA), +1,044% in Tesla (TSLA), +611% in Liquefied Natural Gas Limited (LNGLY), +324% in Bitcoin Services (BTSC), just to name a few. If you're interested in making triple-digit gains from the world's biggest investment trends BEFORE anyone else, click here to learn more about Matt McCall and his investments strategy today. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 9 Retail Stocks Goldman Sachs Says Are Ready to Rip * 7 Services Stocks to Buy for the Rest of 2019 * 6 Stocks to Buy and 1 to Sell Based on Insider Trading The post 3 Keys to Investing in Next-Gen Healthcare Stocks appeared first on InvestorPlace.Tue, 06 Aug 2019 13:38:09 +0000 —Read more…

MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.

This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.

The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.

The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.

Disclaimer: Past performance is no guarantee of future performance. This product is for educational purposes only. Practical application of the products herein are at your own risk and MarketTamer.com, its partners, representatives and employees assume no responsibility or liability for any use or mis-use of the product. Please contact your financial advisor for specific financial advice tailored to your personal circumstances. Any trades shown are hypothetical example and do not represent actual trades. Actual results may differ. Nothing here in constitutes a recommendation respecting the particular security illustrated.